Tatiana Erazo

My project is focused on the study of the role of Protein arginine methyltransferase-5 (PRMT5) in lymphomagenesis. In particular, I am elucidating the mechanism of action of the first selective inhibitor of PRMT5, as well as the effect of PRMT5 deletion in Mantle Cell Lymphoma progression.

During my PhD I was involved in the identification of the interactome of the new MAP kinase ERK5. Moreover, I contributed to the description of a novel   noncanonical mechanism of nuclear translocation of this MAPK and its impact in cancer cell proliferation. This research was carried out at the Neuroscience Institute of the Autonomous University of Barcelona.

My first postdoctoral project was the preclinical development of a new anti-tumor drug, that is currently in Phase 2 Clinical trial. I discovered a new druggable cellular route (PPAR-TRIB3-Akt-mTORC1) that leads to autophagy-mediated cancer cell death.